Key result
Specialized management strategies, including specific stopping rules and the use of novel reversal agents like idarucizumab, are required for patients on DOACs needing emergency invasive procedures.
Why the study?
How should patients taking direct oral anticoagulants be managed when requiring emergency invasive procedures?
Population
Patients taking direct oral anticoagulants (DOACs) who require emergency invasive procedures or surgery
Design
Review
Authors
Loading...
May inform DOAC management in emergencies; hypothesis-generating and requires prospective validation before practice change.
How should patients taking direct oral anticoagulants be managed when requiring emergency invasive procedures?
Specific reversal agents such as idarucizumab and emerging agents like andexanet alfa and ciraparantag offer targeted strategies for managing DOAC-treated patients during emergency procedures.
Jerrold H. Levy (2016) conducted a review in Patients taking direct oral anticoagulants (DOACs) requiring emergency invasive procedures. Management strategies and reversal agents (e.g., idarucizumab, andexanet alfa, ciraparantag) was evaluated. Specialized management strategies, including specific stopping rules and the use of novel reversal agents like idarucizumab, are required for patients on DOACs needing emergency invasive procedures.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: